Arrowhead Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, ARWR, Arrowhead Pharmaceuticals Inc, priceseries

Arrowhead Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
42.81
Close
41.98
High
43.58
Low
41.80
Previous Close
42.92
Daily Price Gain
-0.94
YTD High
70.09
YTD High Date
Jan 3, 2022
YTD Low
39.42
YTD Low Date
Feb 24, 2022
YTD Price Change
-27.99
YTD Gain
-40.00%
52 Week High
93.66
52 Week High Date
Jun 23, 2021
52 Week Low
39.42
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-22.60
52 Week Gain
-35.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 14. 2017
2.01
Mar 6. 2017
2.14
13 Trading Days
6.52%
Link
LONG
Aug 11. 2017
1.84
Sep 14. 2017
2.92
23 Trading Days
58.54%
Link
LONG
Sep 22. 2017
3.55
Oct 10. 2017
4.05
12 Trading Days
14.08%
Link
LONG
Jan 2. 2018
3.72
Feb 2. 2018
5.87
22 Trading Days
57.71%
Link
LONG
Feb 23. 2018
5.80
Mar 19. 2018
7.13
16 Trading Days
22.90%
Link
LONG
May 2. 2018
7.14
Jun 7. 2018
10.15
25 Trading Days
42.16%
Link
LONG
Jun 29. 2018
13.60
Jul 20. 2018
16.08
14 Trading Days
18.25%
Link
LONG
Jan 4. 2019
13.18
Jan 22. 2019
13.91
11 Trading Days
5.54%
Link
LONG
Feb 8. 2019
15.66
Mar 6. 2019
18.80
17 Trading Days
20.06%
Link
LONG
May 21. 2019
21.35
Jun 14. 2019
25.92
17 Trading Days
21.42%
Link
LONG
Jul 12. 2019
27.15
Jul 25. 2019
28.85
9 Trading Days
6.25%
Link
LONG
Oct 2. 2019
28.92
Nov 6. 2019
39.31
25 Trading Days
35.92%
Link
LONG
Nov 8. 2019
42.10
Dec 13. 2019
66.64
24 Trading Days
58.30%
Link
LONG
Apr 6. 2020
28.94
Apr 29. 2020
37.09
16 Trading Days
28.16%
Link
LONG
Jun 18. 2020
36.72
Jul 23. 2020
46.88
24 Trading Days
27.66%
Link
LONG
Oct 15. 2020
48.85
Nov 23. 2020
66.60
27 Trading Days
36.34%
Link
LONG
Dec 4. 2020
65.29
Dec 28. 2020
80.23
15 Trading Days
22.88%
Link
LONG
Jun 4. 2021
76.14
Jun 28. 2021
87.45
16 Trading Days
14.86%
Link
LONG
Nov 1. 2021
70.99
Nov 10. 2021
76.94
7 Trading Days
8.39%
Link
Company Information
Stock Symbol
ARWR
Exchange
NasdaqGS
Company URL
http://www.arrowheadpharma.com
Company Phone
626-304-3400
CEO
Christopher Richard Anzalone
Headquarters
California
Business Address
225 SOUTH LAKE AVENUE, SUITE 1050, PASADENA, CA 91101
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000879407
About

Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Description

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading